Skip to main content
. 2018 Sep 26;24(3):349–357. doi: 10.1634/theoncologist.2018-0150

Figure 3.

image

Cost‐effectiveness acceptability curves for the first‐line and second‐line osimertinib and the standard of care strategies in the U.S. and China.Abbreviations: CNS, central nervous system; QALY, quality‐adjusted life year; SOC, standard care.